This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

VANOS Cream and Skin Barrier Function

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2009 by Oregon Health and Science University.
Recruitment status was:  Recruiting
Medicis Pharmaceutical Corporation
Information provided by:
Oregon Health and Science University Identifier:
First received: January 8, 2009
Last updated: August 11, 2009
Last verified: August 2009
The purpose of this study is to determine the effect of short-term therapy using "VANOS Cream," a super-potent topical steroid cream on skin barrier function in patients with atopic dermatitis. This cream is already approved for this indication, but the investigators will further examine its effects on the skin barrier. This cream is a novel formulation of fluocinonide designed to enhance compliance with a cream base, but have the skin barrier repair properties of an ointment.

Condition Intervention Phase
Atopic Dermatitis Drug: Fluocinonide Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis

Resource links provided by NLM:

Further study details as provided by Oregon Health and Science University:

Primary Outcome Measures:
  • Eczema Severity and Area Index [ Time Frame: 2 Weeks ]

Secondary Outcome Measures:
  • Transepidermal water loss [ Time Frame: 2 weeks ]

Estimated Enrollment: 25
Study Start Date: January 2009
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vanos Cream
glucocorticoid cream
Drug: Fluocinonide
Fluocinonide 0.1% cream topical daily for two weeks


Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of AD according to Hanifin-Rajka criteria (see Appendix B)
  • Age 12 years or older
  • Must have an Investigator's Global Assessment (IGA) Score of Moderate, Severe, or Very Severe (See Appendix C)
  • Must have failed to achieve adequate disease despite adequate topical or systemic therapy
  • Must be a candidate, according to the principal investigator and standard of care, for a super-potent topical steroid course. Subjects that are candidates for super-potent topical steroids are defined as subjects whose disease is not adequately controlled with medium-potency topical steroids or systemic therapy, including phototherapy.

Exclusion Criteria:

  • Active skin infection
  • Hypersensitivity to any ingredients in Vanos cream
  • Previous use of super-potent topical steroids within 2 weeks of starting study (Class I steroid).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00819507

Contact: Maureen Keene 503-228-7350

United States, Oregon
Oregon Health & Science University Department of Dermatology Recruiting
Portland, Oregon, United States, 97239
Principal Investigator: Eric L Simpson, MD         
Sponsors and Collaborators
Oregon Health and Science University
Medicis Pharmaceutical Corporation
  More Information

Responsible Party: Eric Simpson, MD, Oregon Health & Science university Identifier: NCT00819507     History of Changes
Other Study ID Numbers: 4590
Study First Received: January 8, 2009
Last Updated: August 11, 2009

Keywords provided by Oregon Health and Science University:
Skin barrier
Atopic Dermatitis
Effects on skin severity and barrier function

Additional relevant MeSH terms:
Dermatitis, Atopic
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Anti-Allergic Agents processed this record on June 28, 2017